A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma.
Simon GarinetAudrey DidelotLaetitia MarisaGuillaume BeinseMarine SroussiFrançoise Le Pimpec-BarthesElizabeth FabreLaure GibaultPierre Laurent-PuigSophie Mouillet-RichardAntoine LegrasHélène BlonsPublished in: Journal of translational medicine (2023)
This EMT and miR-200-related prognostic signature refines prognosis evaluation independently of tumor stage and paves the way towards assessing the predictive value of this LUAD clustering to optimize perioperative treatment.
Keyphrases
- early stage
- cell proliferation
- long non coding rna
- long noncoding rna
- single cell
- rna seq
- stem cells
- gene expression
- cardiac surgery
- epithelial mesenchymal transition
- squamous cell carcinoma
- acute kidney injury
- patients undergoing
- combination therapy
- radiation therapy
- lymph node
- dna methylation
- rectal cancer
- drug induced
- replacement therapy